Systematic review: The quality of life of patients with biliary atresia

Standard

Systematic review: The quality of life of patients with biliary atresia. / Le, Melanie; Reinshagen, Konrad; Tomuschat, Christian.

In: J PEDIATR SURG, Vol. 57, No. 12, 12.2022, p. 934-946.

Research output: SCORING: Contribution to journalSCORING: Review articleResearch

Harvard

APA

Vancouver

Bibtex

@article{40f4e53bb65641d5be35cfbf5a1f09c8,
title = "Systematic review: The quality of life of patients with biliary atresia",
abstract = "BACKGROUND: The quality of life of patients with Biliary Atresia (BA) have not been systematically examined. The goal of this meta-analysis is to determine patients' postoperative health-related Quality of life (HrQoL) with native or transplanted livers.METHODS: From 2000 to August 2021, a literature-based search for relevant cohorts was conducted using Pubmed/Medline, the Cochrane Library, and Embase. Original research on BA, Hepatoportoenterostomy (HPE), portoenterostomy, Kasai, Liver transplantation and HrQoL was included. Using RevMan, a forest plot analysis of HrQoL after surgical treatment after BA was calculated (version 5.4). Using MetaXL, a pooled prevalence for cholangitis, secondary liver transplantation, or related malformations was computed (version 5.3).RESULTS: Nine studies compared individuals with BA to an age-matched healthy control group. 4/9 (n = 352) of these studies found poorer scores for BA patients, while 5/9 (n = 81) found equivalent health status. Factors associated with HrQoL: older age at the time of the survey was linked to greater HrQoL; whereas females, higher total bilirubin and the amount of immunosuppressive medicines were associated with lower HrQoL in BA patients.CONCLUSION: The current study emphasises the critical need to improve the many parameters influencing HrQoL in BA patients, as well as the methods utilized to assess those factors. This includes immunosuppression, withdrawal from polydrug regimes and recognizing the differences in disease burden between males and females.TYPE OF STUDY: Systematic review.LEVEL OF EVIDENCE: Level III.",
author = "Melanie Le and Konrad Reinshagen and Christian Tomuschat",
note = "Copyright {\textcopyright} 2022 Elsevier Inc. All rights reserved.",
year = "2022",
month = dec,
doi = "10.1016/j.jpedsurg.2022.03.013",
language = "English",
volume = "57",
pages = "934--946",
journal = "J PEDIATR SURG",
issn = "0022-3468",
publisher = "W.B. Saunders Ltd",
number = "12",

}

RIS

TY - JOUR

T1 - Systematic review: The quality of life of patients with biliary atresia

AU - Le, Melanie

AU - Reinshagen, Konrad

AU - Tomuschat, Christian

N1 - Copyright © 2022 Elsevier Inc. All rights reserved.

PY - 2022/12

Y1 - 2022/12

N2 - BACKGROUND: The quality of life of patients with Biliary Atresia (BA) have not been systematically examined. The goal of this meta-analysis is to determine patients' postoperative health-related Quality of life (HrQoL) with native or transplanted livers.METHODS: From 2000 to August 2021, a literature-based search for relevant cohorts was conducted using Pubmed/Medline, the Cochrane Library, and Embase. Original research on BA, Hepatoportoenterostomy (HPE), portoenterostomy, Kasai, Liver transplantation and HrQoL was included. Using RevMan, a forest plot analysis of HrQoL after surgical treatment after BA was calculated (version 5.4). Using MetaXL, a pooled prevalence for cholangitis, secondary liver transplantation, or related malformations was computed (version 5.3).RESULTS: Nine studies compared individuals with BA to an age-matched healthy control group. 4/9 (n = 352) of these studies found poorer scores for BA patients, while 5/9 (n = 81) found equivalent health status. Factors associated with HrQoL: older age at the time of the survey was linked to greater HrQoL; whereas females, higher total bilirubin and the amount of immunosuppressive medicines were associated with lower HrQoL in BA patients.CONCLUSION: The current study emphasises the critical need to improve the many parameters influencing HrQoL in BA patients, as well as the methods utilized to assess those factors. This includes immunosuppression, withdrawal from polydrug regimes and recognizing the differences in disease burden between males and females.TYPE OF STUDY: Systematic review.LEVEL OF EVIDENCE: Level III.

AB - BACKGROUND: The quality of life of patients with Biliary Atresia (BA) have not been systematically examined. The goal of this meta-analysis is to determine patients' postoperative health-related Quality of life (HrQoL) with native or transplanted livers.METHODS: From 2000 to August 2021, a literature-based search for relevant cohorts was conducted using Pubmed/Medline, the Cochrane Library, and Embase. Original research on BA, Hepatoportoenterostomy (HPE), portoenterostomy, Kasai, Liver transplantation and HrQoL was included. Using RevMan, a forest plot analysis of HrQoL after surgical treatment after BA was calculated (version 5.4). Using MetaXL, a pooled prevalence for cholangitis, secondary liver transplantation, or related malformations was computed (version 5.3).RESULTS: Nine studies compared individuals with BA to an age-matched healthy control group. 4/9 (n = 352) of these studies found poorer scores for BA patients, while 5/9 (n = 81) found equivalent health status. Factors associated with HrQoL: older age at the time of the survey was linked to greater HrQoL; whereas females, higher total bilirubin and the amount of immunosuppressive medicines were associated with lower HrQoL in BA patients.CONCLUSION: The current study emphasises the critical need to improve the many parameters influencing HrQoL in BA patients, as well as the methods utilized to assess those factors. This includes immunosuppression, withdrawal from polydrug regimes and recognizing the differences in disease burden between males and females.TYPE OF STUDY: Systematic review.LEVEL OF EVIDENCE: Level III.

U2 - 10.1016/j.jpedsurg.2022.03.013

DO - 10.1016/j.jpedsurg.2022.03.013

M3 - SCORING: Review article

C2 - 35428492

VL - 57

SP - 934

EP - 946

JO - J PEDIATR SURG

JF - J PEDIATR SURG

SN - 0022-3468

IS - 12

ER -